EarningsQ2 2026 Earnings Report
MX:ACAD Q2 2026 EPS Results
Actual EPS$3.26
Consensus EPS$1.23
Beat/MissBeat by +$2.03
One Year Ago EPS$2.90
MX:ACAD Q2 2026 Revenue Results
Actual Revenue$5.57B
Expected Revenue$5.37B
Beat/MissBeat by +$206.43M
YoY Revenue Growth+16.40%
Earnings Announcement Details
QuarterQ2 2026
Date08/04/2026
TimeAfter Close
Conference CallTuesday, August 4, 2026
MX:ACAD Upcoming Earnings
ACADIA Pharmaceuticals's next earnings date is estimated for November 11, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:ACAD Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and clear near-term catalysts: robust Q2 results (total revenues +17%), pronounced DAYBUE STIX uptake (DAYBUE +30% YoY), healthy NUPLAZID growth (+10% YoY) with new prescriptions up 20%, a positive CHMP opinion for trofinetide in Europe, and significant pipeline progress (remlifanserin Phase II enrollment complete, Fast Track designation, top-line data expected Sep–Oct 2026). Offsetting factors include rising SG&A, sizable gross‑to‑net adjustments (~24%), a lowered R&D spend guidance due to a shifted BD milestone, reimbursement and pricing uncertainties in Europe, and dependency on upcoming pivotal readouts (creating execution/timing risk). Overall, the positives — strong sales, upgraded DAYBUE guidance, regulatory wins and a deepening pipeline with imminent binary catalysts — outweigh the operational and timing risks presented.Company Guidance
Strong Q2 Financial Performance
Total revenues of $308 million in Q2 2026, representing +17% year-over-year on an adjusted basis; company now guiding full-year 2026 revenues of $1.24 billion to $1.30 billion.
DAYBUE Sales Acceleration and U.S. STIX Uptake
DAYBUE net sales were $125 million in Q2 (+30% YoY), with ~27% of that growth attributable to volume; approximately 40% of U.S. DAYBUE patients were receiving DAYBUE STIX by quarter end; DAYBUE 2026 guidance raised to $480M–$510M (from $460M–$490M) and management reiterated a $700M sales ambition for 2028.
NUPLAZID Continued Momentum
NUPLAZID net sales were $183 million in Q2 (+10% YoY on an adjusted basis), driven by ~8% volume growth; new patient prescriptions increased ~20% YoY (highest quarterly volume since Q1 2018); NUPLAZID full‑year guidance unchanged at $760M–$790M; expanded field force has reached over 12,000 priority HCPs since February.
Pipeline Progress — remlifanserin
Phase II enrollment for remlifanserin in Alzheimer's disease psychosis (RADIANT) is complete (Phase II portion enrolled 363 patients); the program received FDA Fast Track designation; top-line Phase II results are expected in September–October 2026; Phase III screening/enrollment has commenced; company cites peak sales potential of ~$4 billion across ADP and Lewy body dementia psychosis (management's rough split ~60% ADP / 40% LBD).
Regulatory Milestones for Trofinetide (DAYBUE)
Positive CHMP opinion received following re-examination for Rett syndrome in the EU; European Commission decision expected in Q3 2026 with a planned Germany launch in early Q4; trofinetide Phase III readout in Japan expected in Sep–Nov 2026 and a regulatory submission in Japan planned for 2027; named patient supply programs remain a contributor to international growth.
Cash Position and Financial Flexibility
Cash balance of $956 million at quarter end, providing runway and flexibility to fund commercial growth, advance the pipeline and pursue business development opportunities.
Refined R&D Prioritization
R&D spend guidance lowered to $355M–$380M (from $385M–$410M), reflecting portfolio prioritization and shifting of a BD milestone to 2027 — indicates cost discipline while keeping key programs active.
MX:ACAD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed